| Hazard Information | Back Directory | [Uses]
Pam3CSK4 TFA is a toll-like receptor 1/2 (TLR1/2) agonist with an EC50 of 0.47 ng/mL for human TLR1/2[1]. | [in vivo]
Pam3CSK4 (5 mg/kg; i.p.; once a day for 9 days) alters brain, spleen and liver weights in neonatal mice[3]. | Animal Model: | Time-mated pregnant C57BL/6 wild-type mice; B6.129-Tlr2tm1Kir/J (TLR2 -deficient) mice[3] | | Dosage: | 5 mg/kg | | Administration: | Intraperitoneally (i.p.); once a day for 9 days | | Result: | After repeated administration from postnatal day (PND3) to PND11, brain weight was decreased compared with endotoxin-free saline-treated animals at PND12. Decreased volume of cerebral gray matter, white matter in the forebrain and cerebellar molecular layer that was accompanied by an increase in spleen and liver weight at PND12. |
| [IC 50]
TLR1; TLR2 | [References]
[1] Irvine KL, et al. The molecular basis for recognition of bacterial ligands at equine TLR2, TLR1 and TLR6. Vet Res. 2013 Jul 4;44:50. DOI:10.1186/1297-9716-44-50
[2] Chen Y, et al. TLR2 agonist Pam3CSK4 enhances the antibacterial functions of GM-CSF induced neutrophils to methicillin-resistant Staphylococcus aureus. Microb Pathog. 2019 May;130:204-212. DOI:10.1016/j.micpath.2019.02.030
[3] Du X, et al. Systemic stimulation of TLR2 impairs neonatal mouse brain development. PLoS One. 2011 May 6;6(5):e19583. DOI:10.1371/journal.pone.0019583 |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
|